Drug Profile

Asedebart - Lundbeck A/S

Alternative Names: Lu-AG13909

Latest Information Update: 26 Aug 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Lundbeck A/S
Class Monoclonal antibodies
Mechanism of Action Corticotropin receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Congenital adrenal hyperplasia; Pituitary ACTH hypersecretion
New Molecular Entity Yes

Highest Development Phases

Phase II Pituitary ACTH hypersecretion
Phase I/II Congenital adrenal hyperplasia

Most Recent Events

24 Aug 2026 Asedebart receives Orphan Drug status for Pituitary ACTH Hypersecretion in European Union
15 Jun 2026 Efficacy and adverse events data from a phase II trial in Pituitary ACTH Hypersecretion released by Lundbeck
18 May 2026 Asedebart - Lundbeck receives Orphan Drug status for Congenital adrenal hyperplasia in Japan

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com